Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | PER2 | O15055 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6548967 | 0.83 | ACE (0.59) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5312378 | 0.83 | PIK3CD (0.55) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2617908 | 0.80 | TSHR (0.41) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3897710 | 0.79 | APEX1 (0.49) | TSHRAPEX1BLMACERAB9A | |
| SCHEMBL9789683 | 0.79 | APEX1 (0.49) | TSHRAPEX1BLMACERAB9A | |
| SCHEMBL2442408 | 0.79 | TSHR (0.48) | TSHRAPEX1BLMACERAB9A | |
| SCHEMBL2442413 | 0.79 | TSHR (0.48) | TSHRAPEX1BLMACERAB9A | |
| SCHEMBL9789664 | 0.79 | APEX1 (0.49) | TSHRAPEX1BLMACERAB9A | |
| SCHEMBL24879759 | 0.79 | PIK3CD (0.50) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5505483 | 0.79 | ACE (0.51) | TSHRAPEX1BLMACEPER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | claimed |
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4294382-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | Merck Sharp & Dohme LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-115594680-A | TEAD inhibitor | 武汉人福创新药物研发中心有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023280254-A1 | TEAD INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280254-A1 | TEAD INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022177869-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022177869-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| US-9399033-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2015-12-24 | — | — | US | disclosed |
| US-9096517-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096517-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-8785661-B2 | Oligome-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
| CN-1268111-A | Iodopropagylamine compounds, and industrial antimicrobial and antifungal agents, algicides, and antifouling agents containing the same | NISSAN CHEMICAL IND LTD (JP) | 2000-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | PIK3CD 2716/4885CHRM2 3885/4885CHRM4 2639/4885 |
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | TEAD2, TEAD3, TEAD4 | PIK3CD 1127/4885CHRM2 1686/4885CHRM4 1394/4885 |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | PIK3CD 2716/4885CHRM2 3885/4885CHRM4 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.